Polatuzumab vedotin with rituximab and bendamustine for treating relapsed or refractory diffuse large B‑cell lymphoma
Closed for comments This consultation ended on at Request commenting lead permission
The 4 technology appraisal committees are standing advisory committees of NICE. This topic was considered by committee A.
Committee members are asked to declare any interests in the technology to be appraised. If it is considered there is a conflict of interest, the member is excluded from participating further in that appraisal.
The minutes of each appraisal committee meeting, which include the names of the members who attended and their declarations of interests, are posted on the NICE website.
Each technology appraisal is assigned to a team consisting of 1 or more health technology analysts (who act as technical leads for the appraisal), a technical adviser and a project manager.
ISBN: [to be added at publication]